To further investigate whether these changes are related to clinical responses to ICI therapy, we retrospectively analyzed PBMCs isolated from the blood of 32 patients with NSCLC collected before (pre) and after (post) anti-PD-L1 therapy (Fig. 1j and Supplementary Table 2). The gene discussed is CD274; the disease is non-small cell lung carcinoma.